substantive-fix: address reviewer feedback (date_errors)

- Source: inbox/queue/2025-06-xx-jacc-acc-scientific-statement-obesity-adults-heart-failure.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 1
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Psychiatric pharmacotherapy shows the same benefit-reversion pattern as metabolic drugs but has a mitigation pathway through behavioral intervention that metabolic treatments lack
+confidence: likely
+source: The Lancet Psychiatry, network meta-analysis of 76 RCTs with 17,000+ adults
+created: 2026-04-11
+title: "Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication"
+agent: vida
+scope: causal
+sourcer: The Lancet Psychiatry
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
+
+Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.

domains/health/clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Systematic taxonomy of AI-induced cognitive failures in medical practice, with never-skilling as a categorically different problem from deskilling because it lacks a baseline for comparison
+confidence: experimental
+source: Artificial Intelligence Review (Springer Nature), mixed-method systematic review
+created: 2026-04-11
+title: Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each
+agent: vida
+scope: causal
+sourcer: Artificial Intelligence Review (Springer Nature)
+related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
+---
+
+# Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each
+
+This systematic review identifies three mechanistically distinct pathways through which clinical AI degrades physician competence. **Deskilling** occurs when existing expertise atrophies through disuse: colonoscopy polyp detection dropped from 28.4% to 22.4% after 3 months of AI use, and experienced radiologists showed 12% increased false-positive recalls after exposure to erroneous AI prompts. **Mis-skilling** occurs when clinicians actively learn incorrect patterns from systematically biased AI outputs: in computational pathology studies, 30%+ of participants reversed correct initial diagnoses after exposure to incorrect AI suggestions under time constraints. **Never-skilling** is categorically different: trainees who begin clinical education with AI assistance may never develop foundational competencies. Junior radiologists are far less likely than senior colleagues to detect AI errors — not because they've lost skills, but because they never acquired them. This is structurally invisible because there's no pre-AI baseline to compare against. The review documents mitigation strategies including AI-off drills, structured assessment pre-AI review, and curriculum redesign with explicit competency development before AI exposure. The key insight is that these three failure modes require fundamentally different interventions: deskilling requires practice maintenance, mis-skilling requires error detection training, and never-skilling requires prospective competency assessment before AI exposure.

domains/health/glp-1-nutritional-support-advisory-recommends-snap-enrollment-creating-institutional-contradiction-with-snap-cuts.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Four major medical societies identify food assistance as necessary infrastructure for GLP-1 therapy while Congress cuts the same programs by 186 billion through 2034
+confidence: experimental
+source: OMA/ASN/ACLM/Obesity Society joint advisory SNAP recommendation, OBBBA SNAP cuts
+created: 2026-04-11
+title: GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts
+agent: vida
+scope: structural
+sourcer: OMA/ASN/ACLM/Obesity Society
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+---
+
+# GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts
+
+The joint advisory from OMA, ASN, ACLM, and The Obesity Society explicitly identifies food insecurity and nutrition insecurity as barriers to equitable obesity management with GLP-1s. The screening checklist includes food insecurity, nutrition insecurity, and housing/transportation challenges. The advisory recommends 'eligibility assessment and enrollment support (if eligible) for federal food assistance programs such as SNAP' as part of standard GLP-1 therapy support. This is not peripheral guidance but core to the nutritional priorities framework: GLP-1 therapy requires nutrient-dense, minimally processed diets (80-120g protein/day, multiple micronutrients) while simultaneously suppressing appetite, making food quality critical when food quantity is reduced. The advisory cites evidence that group-based models showed greater weight reduction in majority Latino and low-income households in federally-designated underserved areas, suggesting that nutritional support infrastructure improves outcomes. However, this clinical guidance was published in May/June 2025, the same period as the OBBBA SNAP cuts of 186 billion dollars through 2034. The institutional contradiction is explicit: medical societies identify SNAP as necessary infrastructure for a therapy projected to reach tens of millions of users, while Congress simultaneously cuts access to that infrastructure. This is not a policy debate about SNAP's general value but a direct conflict between healthcare innovation requirements and food policy implementation.

domains/health/glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The appetite suppression mechanism that drives GLP-1 efficacy creates micronutrient deficiency risk requiring dietitian monitoring, but implementation data shows the infrastructure does not exist
+confidence: experimental
+source: "OMA/ASN/ACLM/Obesity Society joint advisory, 92% no dietitian contact finding"
+created: 2026-04-11
+title: GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
+agent: vida
+scope: structural
+sourcer: OMA/ASN/ACLM/Obesity Society
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+---
+
+# GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
+
+GLP-1 receptor agonists suppress appetite as their primary mechanism, reducing caloric intake by 20-30%. This creates systematic micronutrient deficiency risk across iron, calcium, magnesium, zinc, and vitamins A, D, E, K, B1, B12, and C. The joint advisory from four major obesity/nutrition organizations identifies protein intake as 'difficult to achieve' during active weight loss, requiring 1.2-1.6 g/kg/day (versus 0.8 baseline) to preserve lean mass. However, implementation data shows 92% of GLP-1 patients had NO dietitian visit in the 6 months prior to prescription. Only 8.3% had dietitian contact in the 180 days before treatment initiation. This creates a structural care gap: the therapy's mechanism requires continuous nutritional monitoring, but the delivery infrastructure does not exist. As GLP-1 adoption scales from current millions to projected tens of millions of users, this gap widens arithmetically. The advisory recommends regular food logs, nutrient level lab testing (B12, 25(OH)D, iron, folic acid), and body composition monitoring (BIA, DXA) — none of which occur in standard primary care workflows. This is not a temporary implementation lag but a structural mismatch between the therapy's continuous-treatment model and the episodic-care delivery system.

domains/health/glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Low-dose semaglutide demonstrates cardiac remodeling benefits independent of weight loss, suggesting therapeutic utility in non-obese or sarcopenia-vulnerable HFpEF patients
+confidence: experimental
+source: bioRxiv preprint, ZSF1 obese rat model with single-cell RNA sequencing
+created: 2026-04-11
+title: GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+agent: vida
+scope: causal
+sourcer: bioRxiv preprint
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+
+This preprint study used ZSF1 obese rats with spontaneous HFpEF treated with low-dose semaglutide (30 nmol/kg twice weekly) for 16 weeks and found significant attenuation of pathological cardiac and hepatic remodeling independent of weight loss effects. The study employed comprehensive multi-omics approaches including single-cell RNA sequencing and proteomics to identify the primary mechanisms: attenuated cardiac and hepatic fibrosis and reverse lipid transport. The weight-independence is critical because it suggests the cardioprotective benefits occur through mechanisms distinct from body weight reduction. This has immediate clinical implications: (1) non-obese HFpEF patients who would not qualify under current BMI ≥30 criteria could benefit from GLP-1 therapy, and (2) sarcopenic HFpEF patients could potentially receive lower doses that preserve cardiac benefits while reducing appetite suppression and lean mass loss. The mechanistic depth (single-cell RNA sequencing on cardiac tissue) and multi-omics validation strengthen confidence in the weight-independent pathway. This finding could resolve the clinical paradox where HFpEF patients most in need of cardiac protection are also most vulnerable to GLP-1-induced sarcopenia at standard doses.

domains/health/glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Direct GLP-1R cardiac effects (cardiomyocyte protection, anti-fibrotic, anti-inflammatory) are distinct from metabolic/weight effects, resolving the STEER counterintuitive finding
+confidence: experimental
+source: "Circulation: Heart Failure mechanistic review, STEER study comparative data"
+created: 2026-04-11
+title: GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
+agent: vida
+scope: causal
+sourcer: "Circulation: Heart Failure (AHA Journals)"
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
+
+GLP-1 receptors are expressed directly in heart, blood vessels, kidney, brain, adipose tissue, and lung. The review identifies multiple weight-independent mechanisms: direct GLP-1R-mediated cardiomyocyte protection, anti-fibrotic effects in cardiac tissue, anti-inflammatory signaling in cardiac macrophages, and improved renal sodium handling independent of weight changes. This mechanistic framework explains the STEER study finding where semaglutide showed 29-43% lower MACE than tirzepatide in matched ASCVD patients despite tirzepatide being superior for weight loss. The key distinction is that tirzepatide's GIPR agonism adds metabolic benefit but may not add cardiovascular benefit beyond GLP-1R effects alone. This suggests the GLP-1R-specific cardiac mechanism is the primary driver of cardiovascular benefit, not the weight loss itself. The therapeutic implication is that non-obese HFpEF patients may benefit from GLP-1RAs through these weight-independent mechanisms, and lower doses that minimize appetite suppression while preserving GLP-1R cardiac signaling might provide cardiovascular benefit while reducing sarcopenia risk from excessive lean mass loss.

domains/health/never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "Detection problem unique to never-skilling: a trainee who never develops competence without AI looks identical to a trained clinician who deskilled, but remediation strategies differ fundamentally"
+confidence: experimental
+source: Artificial Intelligence Review (Springer Nature), systematic review of clinical AI training outcomes
+created: 2026-04-11
+title: Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect
+agent: vida
+scope: structural
+sourcer: Artificial Intelligence Review (Springer Nature)
+related_claims: ["[[clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling]]"]
+---
+
+# Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect
+
+Never-skilling presents a unique detection challenge that distinguishes it from deskilling. When a physician loses existing skills through disuse (deskilling), the degradation is detectable through comparison to their previous baseline performance. But when a trainee never acquires foundational competencies because AI was present from the start of their education, there is no baseline to compare against. A junior radiologist who cannot detect AI errors looks identical whether they (a) never learned the underlying skill or (b) learned it and then lost it through disuse — but the remediation is fundamentally different. The review documents that junior radiologists are far less likely than senior colleagues to detect AI errors, but this cannot be attributed to deskilling because they never had the pre-AI skill level to lose. This creates a structural invisibility problem: never-skilling can only be detected through prospective competency assessment before AI exposure, or through comparison to control cohorts trained without AI. The paper argues this requires curriculum redesign with explicit competency development milestones before AI tools are introduced, rather than the current practice of integrating AI throughout training. This has specific implications for medical education policy: if AI is introduced too early in training, the resulting competency gaps may be undetectable until a system-wide failure reveals them.

inbox/archive/health/2025-06-xx-jacc-acc-scientific-statement-obesity-adults-heart-failure.md

@@ -7,9 +7,12 @@ date: 2025-06-13
 domain: health
 secondary_domains: []
 format: scientific-statement
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: high
 tags: [ACC, heart-failure, HFpEF, obesity, GLP-1, semaglutide, tirzepatide, sarcopenia, clinical-guidance, 2025]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2025-08-xx-springer-clinical-ai-deskilling-misskilling-neverskilling-mixed-method-review.md

@@ -7,10 +7,13 @@ date: 2025-08-01
 domain: health
 secondary_domains: [ai-alignment]
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: high
 tags: [clinical-AI, deskilling, automation-bias, medical-training, never-skilling, mis-skilling, physician, safety]
 flagged_for_theseus: ["Three-pathway deskilling model extends KB's existing automation bias framework; 'never-skilling' is a novel category not yet in KB"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2025-09-26-biorxiv-low-dose-glp1-cardiac-remodeling-hfpef-independent-weight-loss.md

@@ -7,9 +7,12 @@ date: 2025-09-26
 domain: health
 secondary_domains: []
 format: preprint
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: medium
 tags: [GLP-1, HFpEF, cardiac-remodeling, weight-independent, mechanism, fibrosis, semaglutide, low-dose, single-cell-RNA]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2025-12-xx-lancet-psychiatry-antidepressant-deprescribing-nma-slow-taper-therapy.md

@@ -7,9 +7,12 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: high
 tags: [antidepressant, depression, discontinuation, relapse, CBT, psychotherapy, continuous-treatment-model, pharmacotherapy]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2025-xx-ahajournals-glp1-hfpef-weight-dependent-independent-mechanisms-circulation.md

@@ -7,9 +7,12 @@ date: 2025-06-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: medium
 tags: [GLP-1, HFpEF, mechanism, weight-independent, cardiac, GLP-1R, GIPR, tirzepatide, semaglutide, STEER]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-xx-pubmed-glp1-micronutrient-nutritional-deficiencies-narrative-review.md

@@ -7,9 +7,12 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: high
 tags: [GLP-1, micronutrient, deficiency, nutrition, vitamin-D, iron, calcium, protein, sarcopenia, monitoring, 2026]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/null-result/2025-08-xx-lancet-preserving-clinical-skills-age-ai-assistance.md

@@ -7,10 +7,11 @@ date: 2025-08-12
 domain: health
 secondary_domains: [ai-alignment]
 format: commentary
-status: unprocessed
+status: null-result
 priority: medium
 tags: [clinical-AI, deskilling, never-skilling, medical-training, colonoscopy, physician-skills, Lancet]
 flagged_for_theseus: ["Lancet editorial on deskilling as a mainstream safety concern; 'never-skilling' framing gaining institutional recognition"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content